Acute anterior circulation cerebral infarction within 1 week of onset
Conditions
Interventions
Treatment group:Anisodine Hydrobromide Injection 2mg qd Intravenous drip, a total of 7-10 days
Control group:Treatment is given in accordance with the 2018 Chinese Guidelines for ischemic Stroke
Sponsors
General Hospital of PLA North Theater Command
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Aged 18 years and above, regardless of gender; 2.Ischemic stroke within 1 week of onset; 3.Patients with anterior circulation cerebral infarction; 4.First onset, or previous stroke but mRS<=11 before onset; 5.The degree of neurological impairment (NIHSS) score ranged from 5 to 20; 6.Understand and sign informed consent voluntarily.
Exclusion criteria
Exclusion criteria: 1.Patients receiving intravenous thrombolysis or mechanical thrombolysis; 2.Severe consciousness disorder (NIHSS score Ia>=2 points); 3.Cranial imaging examination confirmed that there are similar symptoms such as brain tumor encephalitis brain abscess, or confirmed that there are hemorrhagic cerebral infarction and so on; 4.A person with a serious heart disease, serious arrhythmia, or heart failure; 5.Severe abnormal liver and kidney function (laboratory indicator of liver function ALT> 1.5 ULN, laboratory indicator of kidney function Cr> 1.5 ULN); 6.Patients with a history of mental illness or dementia; 7.Associated with malignancy of any organ or system, or undergoing antitumor therapy, expected survival <3 months; 8.Significant drug or alcohol abuse; 9.Allergic constitution and allergy to two or more drugs or food; Or is known to be allergic to this drug ingredient; 10.A woman who is already pregnant and has a pregnancy plan or is breast-feeding; 11.Participated in other clinical trials in the past 3 months; 12.The investigators determined that the patients were not eligible for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Randomize the proportion of good prognosis (mRS 0-2) at 90 days; | — |
Secondary
| Measure | Time frame |
|---|---|
| MRS score of 90 days after onset;Percentage of mRS 0-1 patients 90 days after onset;NIHSS score for 14 days of medication;The 90-day all-cause mortality rate;Incidence of combined vascular events at 90 days; | — |
Countries
China
Contacts
Public ContactChen Huisheng
Outcome results
None listed